The DUAL VII trial confirmed that IDegLira has comparable glycaemic effects to MDI in patients with type 2 diabetes uncontrolled on basal insulin, but with less hypoglycaemia and a more beneficial effect on body weight. Here, INS is linked to type 2 diabetes mellitus.